Reviewing Elanco Animal Health (NYSE:ELAN) and Unicycive Therapeutics (NASDAQ:UNCY)

Elanco Animal Health (NYSE:ELAN) and Unicycive Therapeutics (NASDAQ:UNCY) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares Elanco Animal Health and Unicycive Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.71 billion	2.37	-$232.00 million	($0.41)	-54.61
Unicycive Therapeutics	$680,000.00	196.59	-$26.56 million	($1.75)	-2.74

Unicycive Therapeutics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Elanco Animal Health and Unicycive Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Analyst Recommendations

This is a breakdown of recent ratings for Elanco Animal Health and Unicycive Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1	2	9	1	2.77
Unicycive Therapeutics	1	1	5	0	2.57

Elanco Animal Health presently has a consensus target price of $29.09, indicating a potential upside of 29.92%. Unicycive Therapeutics has a consensus target price of $18.75, indicating a potential upside of 290.62%. Given Unicycive Therapeutics’ higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Elanco Animal Health.

Risk and Volatility

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.

Summary

Elanco Animal Health beats Unicycive Therapeutics on 8 of the 15 factors compared between the two stocks.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.